MA33297B1 - Production de nanoparticules encapsulées à des fractions volumiques élevées - Google Patents

Production de nanoparticules encapsulées à des fractions volumiques élevées

Info

Publication number
MA33297B1
MA33297B1 MA34384A MA34384A MA33297B1 MA 33297 B1 MA33297 B1 MA 33297B1 MA 34384 A MA34384 A MA 34384A MA 34384 A MA34384 A MA 34384A MA 33297 B1 MA33297 B1 MA 33297B1
Authority
MA
Morocco
Prior art keywords
biologically active
production
coated nanoparticles
compositions
methods
Prior art date
Application number
MA34384A
Other languages
Arabic (ar)
English (en)
Inventor
Aaron Dodd
Felix Meiser
Adrian Russell
Marck Norret
H William Bosch
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901744A external-priority patent/AU2009901744A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33297B1 publication Critical patent/MA33297B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/18—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/14—Mills in which the charge to be ground is turned over by movements of the container other than by rotating, e.g. by swinging, vibrating, tilting
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

La présente invention concerne des procédés de production de particules d'une matière biologiquement active qui fait appel à des processus de broyage à sec, ainsi que des compositions comprenant de telles matières, des médicaments produits au moyen desdites matières biologiquement actives sous forme particulaire et/ou des compositions, et concerne des méthodes de traitement d'un animal, y compris l'homme, au moyen d'une quantité thérapeutiquement efficace desdites matières biologiquement actives administrées à l'aide desdits médicaments.
MA34384A 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées MA33297B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17227809P 2009-04-24 2009-04-24
AU2009901744A AU2009901744A0 (en) 2009-04-24 Production of Encapsulated Nanoparticles at High Volume Fractions
PCT/AU2010/000464 WO2010121320A1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées

Publications (1)

Publication Number Publication Date
MA33297B1 true MA33297B1 (fr) 2012-05-02

Family

ID=43010603

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34384A MA33297B1 (fr) 2009-04-24 2010-04-23 Production de nanoparticules encapsulées à des fractions volumiques élevées

Country Status (21)

Country Link
US (6) US20120165410A1 (fr)
EP (2) EP3338766A1 (fr)
JP (2) JP6141012B2 (fr)
KR (3) KR101743896B1 (fr)
CN (2) CN102438593A (fr)
AP (1) AP3138A (fr)
AU (1) AU2010239159C1 (fr)
BR (1) BRPI1014878A2 (fr)
CA (1) CA2759102A1 (fr)
CO (1) CO6470805A2 (fr)
DK (1) DK2421509T3 (fr)
EA (1) EA201171279A1 (fr)
IL (2) IL254370B2 (fr)
MA (1) MA33297B1 (fr)
MX (1) MX356518B (fr)
MY (1) MY159098A (fr)
NZ (1) NZ595973A (fr)
SG (1) SG175309A1 (fr)
UA (1) UA110322C2 (fr)
WO (1) WO2010121320A1 (fr)
ZA (1) ZA201108651B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
CA2759109A1 (fr) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Une forme de dosage solide de ciprofloxacine ayant des particules de petites taille et des caracteristiques de manipulation de poudre ameliorees
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
CA2759113C (fr) * 2009-04-24 2017-12-12 Iceutica Pty Ltd Nouvelle formulation de metaxalone
CN102438592B (zh) * 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
TWI599360B (zh) * 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
EP2712628B1 (fr) 2012-09-28 2016-08-10 Shanta Banerjee Composition destinée à être utilisée en tant que médicament ou aliment diététique, en particulier dans la prévention et/ou le traitement du diabète et de maladies associées au diabète
EP2961533B1 (fr) * 2013-02-28 2021-10-13 Sun Chemical Corporation Procede continu de broyage avec microparticules contenues
US20160159756A1 (en) * 2013-07-22 2016-06-09 Iceutica Inc. Formulation of metaxalone
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES2542088B1 (es) * 2014-01-29 2016-05-05 Enoc Solutions, S.L. Composición de azufre liposomado
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN104174468B (zh) * 2014-08-27 2016-06-15 上海延安药业有限公司 粘稠性药物锆珠研磨方法
JP2018515416A (ja) * 2015-05-20 2018-06-14 ユニヴェルシテ ピエール エ マリ キュリ（パリ ６） Ｂｐ、ｂ１２ｐ２およびそれらの混合物の、特にナノ粉末としての製造のためのメカノケミカル方法
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US9975255B1 (en) * 2016-12-15 2018-05-22 Jabil Inc. Apparatus, system and method for providing a conformable vacuum cup for an end effector
CN107417640B (zh) * 2017-02-22 2019-03-26 浙江大学 纳米噻唑锌的制备方法
CN107198677B (zh) * 2017-05-25 2021-07-09 长春金赛药业有限责任公司 黄体酮混悬型长效注射剂及其制备方法和黄体酮混悬注射粉针
KR102105872B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 구리 나노콜로이드 분산체 및 이의 용도
EP3807287B1 (fr) 2018-06-15 2025-07-30 Liliana Patricia RAMIREZ RIOS Complexes métalliques de beta-dicétones et/ou de polyphénols par chimie verte, procédé de préparation, écran solaire, correcteur de teint de la peau ou des cheveux, teinture capillaire et utilisations associés
CN108902480A (zh) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 一种提高饲料中微量添加物均匀度和生物利用度的方法
CN108904506A (zh) * 2018-07-27 2018-11-30 河南大华生物技术有限公司 一种地克珠利纳米粉末及其制备方法
UY38386A (es) * 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
KR102359021B1 (ko) * 2019-07-29 2022-02-07 (주)케나프 가용성 플라보노이드 및 폴리페놀의 함량을 증진시키는 케나프 종자의 가공방법 및 이의 가공물
CN113133970A (zh) 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
CN112674302A (zh) * 2021-01-07 2021-04-20 贵州山珍宝绿色科技开发有限公司 一种百香果刺梨果糕的制备方法
WO2022187222A1 (fr) * 2021-03-03 2022-09-09 Pulmatrix Operating Company, Inc. Formulations de poudre sèche de dihydroergotamine et leurs procédés d'utilisation
CN113729011A (zh) * 2021-07-30 2021-12-03 安徽瑞然生物药肥科技有限公司 草甘膦可溶粒剂及其生产方法
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법
CN114210995B (zh) * 2021-12-17 2023-03-10 浙江大学 一种利用牛蒡根提取液制备纳米银颗粒的方法、产品和应用
EP4209212A1 (fr) * 2022-01-05 2023-07-12 HWI pharma services GmbH Composition aqueuse comprenant des avermectines
CN114671704B (zh) * 2022-04-22 2023-04-18 广州粤瓷新材料有限公司 一种低膨胀多孔堇青石及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
JP4763957B2 (ja) * 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
EP1313451B1 (fr) 2000-08-31 2009-03-11 Jagotec AG Particules broyees
EP2283818B1 (fr) 2000-11-30 2017-08-02 Vectura Limited Procede de preparation de particules destinees a etre utilisees dans une composition pharmaceutique
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
KR20060024927A (ko) * 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
CN101094659A (zh) * 2004-12-31 2007-12-26 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
WO2006084320A1 (fr) 2005-02-08 2006-08-17 Sugar Steel Engineering Pty Ltd Barre d'armature
WO2007070851A2 (fr) * 2005-12-15 2007-06-21 Acusphere, Inc. Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
JP2007169226A (ja) * 2005-12-22 2007-07-05 Ono Pharmaceut Co Ltd 固体分散体
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
BRPI0713053A2 (pt) * 2006-06-30 2012-07-17 Iceutica Pty Ltd métodos para a preparação de compostos biologicamente ativos na forma nanoparticulada
DK2054042T3 (da) * 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US8568696B2 (en) * 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material

Also Published As

Publication number Publication date
CO6470805A2 (es) 2012-06-29
AP3138A (en) 2015-02-28
KR20150032759A (ko) 2015-03-27
MY159098A (en) 2016-12-15
US20120165410A1 (en) 2012-06-28
AP2011005993A0 (en) 2011-12-31
KR20120030384A (ko) 2012-03-28
JP6141012B2 (ja) 2017-06-07
DK2421509T3 (en) 2018-02-26
ZA201108651B (en) 2013-01-30
KR20160138326A (ko) 2016-12-02
MX356518B (es) 2018-05-31
US20240390871A1 (en) 2024-11-28
SG175309A1 (en) 2011-11-28
US20180243707A1 (en) 2018-08-30
BRPI1014878A2 (pt) 2016-05-03
NZ595973A (en) 2014-02-28
IL254370B1 (en) 2023-08-01
WO2010121320A1 (fr) 2010-10-28
US20150306556A1 (en) 2015-10-29
IL215867A0 (en) 2012-01-31
AU2010239159B2 (en) 2014-06-12
IL254370A0 (en) 2017-11-30
EA201171279A1 (ru) 2012-05-30
CN102438593A (zh) 2012-05-02
US20200316546A1 (en) 2020-10-08
IL254370B2 (en) 2023-12-01
KR101743896B1 (ko) 2017-06-05
EP2421509A4 (fr) 2013-01-09
AU2010239159A1 (en) 2011-11-10
AU2010239159C1 (en) 2014-10-16
EP2421509A1 (fr) 2012-02-29
CN105663045A (zh) 2016-06-15
JP2017101045A (ja) 2017-06-08
KR101848766B1 (ko) 2018-05-28
JP6534689B2 (ja) 2019-06-26
US20170320030A1 (en) 2017-11-09
UA110322C2 (uk) 2015-12-25
CA2759102A1 (fr) 2010-10-28
EP2421509B1 (fr) 2017-11-22
EP3338766A1 (fr) 2018-06-27
JP2012524716A (ja) 2012-10-18
MX2011011230A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33294B1 (fr) Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA33295B1 (fr) Nouvelle formulation de diclofénac
MX360019B (es) Una formulación novedosa de metaxalona.
PH12016500746B1 (en) A novel formulation of meloxicam
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA35851B1 (fr) Nanoparticules comprenant des matériaux métalliques et d'oxydes d'hafnium, leur préparation et utilisations
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
EA200900330A1 (ru) Аналоги 2-феноксипиримидинона
MA29453B1 (fr) Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta
MA31913B1 (fr) Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
EP2231169A4 (fr) Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
WO2009019307A3 (fr) Compositions à base de calcitonine orale et leurs applications
MA38487A1 (fr) Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)
AU2014208310B2 (en) A Novel Formulation of Diclofenac
NZ710321A (en) Production of encapsulated nanoparticles at high volume fractions